This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Xenetic Biosciences Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Xenetic Biosciences's earnings are forecast to decline at 37.8% per annum while its annual revenue is expected to grow at 7% per year. EPS is expected to grow by 30.6% per annum.

Anahtar bilgiler

-37.8%

Kazanç büyüme oranı

30.6%

EPS büyüme oranı

Biotechs kazanç büyümesi	35.0%
Gelir büyüme oranı	7.0%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	16 May 2023

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:3XB0 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2025	2	-17	N/A	N/A	1
12/31/2024	2	-11	N/A	N/A	1
12/31/2023	2	-7	N/A	N/A	1
3/31/2023	2	-6	-4	-4	N/A
12/31/2022	2	-7	-5	-5	N/A
9/30/2022	2	-7	-6	-5	N/A
6/30/2022	1	-7	-6	-5	N/A
3/31/2022	1	-6	-5	-5	N/A
12/31/2021	1	-6	-5	-5	N/A
9/30/2021	1	-5	-4	-4	N/A
6/30/2021	1	-11	-4	-4	N/A
3/31/2021	1	-11	-5	-5	N/A
12/31/2020	0	-11	-4	-4	N/A
9/30/2020	0	-11	-5	-5	N/A
6/30/2020	0	-14	-6	-6	N/A
3/31/2020	0	-14	-6	-6	N/A
12/31/2019	0	-18	-6	-6	N/A
9/30/2019	N/A	-19	-6	-6	N/A
6/30/2019	N/A	-10	-5	-5	N/A
3/31/2019	N/A	-11	-6	-6	N/A
12/31/2018	N/A	-7	-6	-6	N/A
9/30/2018	8	-1	-1	-1	N/A
6/30/2018	8	-2	-1	-1	N/A
3/31/2018	8	-3	0	0	N/A
12/31/2017	8	-4	1	1	N/A
9/30/2017	3	-12	-8	-8	N/A
6/30/2017	3	-13	-7	-7	N/A
3/31/2017	3	-58	-7	-7	N/A
12/31/2016	3	-58	N/A	-9	N/A
9/30/2016	N/A	-57	N/A	-5	N/A
6/30/2016	N/A	-60	N/A	-6	N/A
3/31/2016	N/A	-14	N/A	-5	N/A
12/31/2015	N/A	-13	N/A	-5	N/A
9/30/2015	N/A	-13	N/A	-7	N/A
6/30/2015	N/A	-11	N/A	-8	N/A
3/31/2015	N/A	-13	N/A	-11	N/A
12/31/2014	N/A	-14	N/A	-13	N/A
9/30/2014	N/A	-14	N/A	-12	N/A
6/30/2014	N/A	-13	N/A	-12	N/A
3/31/2014	1	-11	N/A	-9	N/A
12/31/2013	1	-9	N/A	-6	N/A
9/30/2013	1	-7	N/A	-5	N/A
6/30/2013	1	-6	N/A	-5	N/A
3/31/2013	0	-6	N/A	-5	N/A
12/31/2012	0	-6	N/A	-6	N/A
9/30/2012	0	-6	N/A	-6	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 3XB0 is forecast to remain unprofitable over the next 3 years.

Kazançlar ve Piyasa: 3XB0 is forecast to remain unprofitable over the next 3 years.

Yüksek Büyüme Kazançları: 3XB0 is forecast to remain unprofitable over the next 3 years.

Gelir ve Pazar: 3XB0's revenue (7% per year) is forecast to grow faster than the German market (4.6% per year).

Yüksek Büyüme Geliri: 3XB0's revenue (7% per year) is forecast to grow slower than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if 3XB0's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Xenetic Biosciences Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Xenetic Biosciences, Inc. Announces the Appointment of James Parslow as Interim Chief Executive Officer

CLS Therapeutics Discloses its Views on Xenetic Biosciences

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of Its DNase-Based Oncology Platform

Xenetic Biosciences, Inc., Annual General Meeting, Dec 06, 2023

First quarter 2023 earnings released: US$0.056 loss per share (vs US$0.12 loss in 1Q 2022)

Full year 2022 earnings released: US$0.46 loss per share (vs US$0.55 loss in FY 2021)

Xenetic Biosciences, Inc., Annual General Meeting, Dec 21, 2022

Xenetic Biosciences Receives a Non-Compliance Letter from Nasdaq

Xenetic Biosciences, Inc. Announces the Appointment of Jonathan Spicer to its Scientific Advisory Board

Third quarter 2022 earnings released: US$0.056 loss per share (vs US$0.13 loss in 3Q 2021)

Xenetic Biosciences, Inc., Annual General Meeting, Dec 07, 2022

Xenetic Biosciences, Inc. announced that it expects to receive $0.488835 million in funding from CLS Therapeutics, Inc.

Xenetic Biosciences, Inc. Appoints Allan Tsung, to Its Scientific Advisory Board

Second quarter 2022 earnings released: US$0.19 loss per share (vs US$0.13 loss in 2Q 2021)

Xenetic Biosciences Receives Written Notification from the Listing Qualifications Department of the Nasdaq

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.15 loss in 1Q 2021)

Xenetic Biosciences, Inc. announced that it has received $0.86625 million in funding

High number of new directors

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$1.20 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.15 loss in 2Q 2020)

High number of new and inexperienced directors

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin